Abeona Therapeutics Targets Mid-2027 Phase III Start for ABO-801 Amid High Revenue Projections
Abeona Therapeutics (ABEO) has announced a strategic timeline aiming to initiate the Phase III clinical trial for its candidate ABO-801 by mid-2027. The company is positioning itself for significant commercial growth, projecting peak annual revenue potential exceeding $750 million from its therapeutic pipeline. Management emphasized that the current period is critical for building the commercial infrastructure required for ZEVASKYN. As part of a broader strategy to diversify opportunities, the company is focusing on strengthening its foundation to support upcoming clinical milestones and long-term market entry.
Tickers: $ABEO
Topics: commercialization growth strategy quarterly earnings